We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 26, 2021

Metabolic Dysfunction–Associated Fatty Liver Disease and Development of Subclinical Atherosclerosis



Additional Info

The Progression and Regression of Metabolic Dysfunction-Associated Fatty Liver Disease are Associated With the Development of Subclinical Atherosclerosis: A Prospective Analysis
Metab. Clin. Exp. 2021 Jul 01;120(xx)154779, S Liu, J Wang, S Wu, J Niu, R Zheng, L Bie, Z Xin, S Wang, H Lin, Z Zhao, T Wang, M Xu, J Lu, Y Chen, Y Xu, W Wang, G Ning, Y Bi, M Li, Y Xu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading